NCT03455244

Brief Summary

This is a prospective, observational, single-center, single-arm, clinical trial designed to assess the efficacy of FFRangio in measuring FFR obtained from angiography compared to Invasive FFR for diagnosing hemodynamically significant coronary stenosis in Multi-Vessel Disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 14, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 28, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 6, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 2, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 2, 2018

Completed
Last Updated

June 25, 2018

Status Verified

June 1, 2018

Enrollment Period

6 months

First QC Date

February 28, 2018

Last Update Submit

June 21, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Sensitivity and specificity of the dichotomously scored FFRangio measured index compared to invasive FFR

    Sensitivity and specificity of the dichotomously scored FFRangio measured index per vessel as compared with invasively-derived FFR; Index ≤ 0.80 is scored "positive" while Index \> 0.8 is negative.

    1 hour

Secondary Outcomes (2)

  • Continuously scored FFR (FFRangio and Invasive FFR).

    1 hour

  • Accuracy, Positive predictive value and negative predictive value per vessel and per lesion

    1 hour

Interventions

FFRangioDEVICE

FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure. The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects with stable angina, unstable angina or NSTEMI who are referred to coronary angiography, have multi-vessel coronary artery disease and have an invasive FFR measurement at two lesions at minimum. Each subject will undergo both the standard invasive FFRs and the investigational FFRangio.

You may qualify if:

  • \>18 years of age.
  • Patients with stable angina or unstable angina or NSTEMI, with at least 1 stenoses ≥ 50% in two main vessels (LAD, LCX and/or RCA) each and in whom invasive FFR is being assessed at these stenoses.
  • Patients undergoing invasive FFR with Adenosine, ATP or Papaverine used as hyperemic stimulus.
  • Written, informed consent.

You may not qualify if:

  • Contraindication for FFR examination or administration of vasodilators.
  • Clinical presentation of an acute infarct (STEMI) or presented with STEMI in past year.
  • CTO in a target vessel.
  • Prior CABG, valvular surgery, TAVI/TAVR, or heart transplantation.
  • Known LVEF ≤45%.
  • Arteries supplying akinetic or severe hypokinetic territories if already known based on prior imaging.
  • TIMI Grade 2 or lower at baseline.
  • Target lesions involve Left Main (stenosis ≥50%.)
  • In-stent restenosis in a target vessel.
  • Heavily diffused atherosclerosis diseases defined as the presence of diffuse, serial gross luminal irregularities present in the majority of the coronary tree.
  • Target coronary vessels are supplied by major collaterals.
  • Lesion is in ectatic segment which includes dilatation in diameter at least 1.5 times that of the adjacent normal coronary artery.
  • Coronary angiograms not acquired per instructions as defined in the Study Protocol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gifu Heart Center

Gifu, 500-8384, Japan

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2018

First Posted

March 6, 2018

Study Start

November 14, 2017

Primary Completion

May 2, 2018

Study Completion

May 2, 2018

Last Updated

June 25, 2018

Record last verified: 2018-06

Data Sharing

IPD Sharing
Will not share

Locations